Validation in a broader cohort of patients was supported by an in silico analysis of the REMBRANDT glioma dataset, which showed a strong positive correlation between KDM2B expression with both CD133 and SOX2 (Fig. S2A). The gene discussed is PROM1; the disease is central nervous system cancer.